Aminoadamantane derivatives as therapeutic agents

Details Aminoadamantane derivatives as therapeutic agents Aminoadamantane derivatives as therapeutic agents

C - Chemistry, Metallurgy

07

C

C07C 219/24 (2006.01) A61K 31/13 (2006.01) A61K 31/16 (2006.01) A61P 25/00 (2006.01) C07C 233/23 (2006.01)

Patent

CA 2400916

The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions. There are a variety of neurological disorders that can be treated using the present invention, including, for example, the following: neurological disorders arising from trauma, ischemic or hypoxic conditions that can be treated include stroke, hypoglycemia, cerebral ischemia, cardiac arrest, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest and hypoglycemic neuronal damage; neurodegenerative disorders such as epilepsy, Alzheimer's disease, Huntington's disease Parkinsonism, and amyotrophic lateral sclerosis; other diseases or disorders such as convulsion, pain, depression, anxiety, schizophrenia, muscle spasms, migraine headaches, urinary incontinence, nicotine withdrawal, opiate tolerance and withdrawal, emesis, brain edema, tardive dyskinesia, AIDS-induced dementia, ocular damage, retinopathy, cognitive disorders, and neuronal injury associated with HIV-infection such as dysfunction in cognition, movement and sensation.

La présente invention concerne des dérivés d'aminoadamantane, des procédés d'obtention de ces dérivés, des compositions contenant ces dérivés d'aminoadamantane et des procédés se rapportant au traitement et à la prévention d'affections neurologiques par utilisation de ces dérivés et compositions. Il y a une variété de troubles neurologiques qui peuvent être traités en utilisant la présente invention incluent, par exemple, ce qui suit: troubles neurologiques post-traumatiques, états ischémiques ou hypoxiques qui peuvent être traités incluent l'accident vasculaire cérébral, hypoglycémie, ischémie cérébrale, arrêt cardiaque, traumatisme de la moelle épinière, traumatisme crânien, hypoxie périnatale, arrêt cardiaque et dommage neuronal; troubles neurodégénératifs tels qu'épilepsie, maladie d'Alzheimer, Parkinsonisme de la chorée de Huntington et sclérose latérale amyotrophique; d'autres affections ou troubles tels que la convulsion, la douleur, la dépression, l'anxiété, la schizophrénie, les spasmes musculaires, maux de tête migraineux, incontinence urinaire, sevrage nicotinique, tolérance aux opiacés et sevrage, vomissement, oedème du cerveau, dyskinésie tardive, démence induite par le SIDA, dommage oculaire, rétinopathie, troubles cognitifs, et lésion neuronale associée à l'infection par VIH tel que le dysfonctionnement affectant la cognition, le mouvement et la sensation.

Affiliated with

Also associated with

Rating

Aminoadamantane derivatives as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aminoadamantane derivatives as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoadamantane derivatives as therapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2047568